Business Of Biotech Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall Tales with Tal)
Jan 6, 2025
Dr. Tal Zaks, CEO of Exsilio Therapeutics and former CMO at Moderna, shares insights on navigating the biotech landscape, including his transition from the COVID-19 crisis to launching his mRNA startup. He discusses the integration of cutting-edge gene therapy technologies and the challenges of moving from academic concepts to therapeutic applications. Zaks emphasizes the importance of public education on mRNA safety, the dual role of medicine in healing and wellness, and the future potential of AI in biotech innovation.
AI Snips
Chapters
Books
Transcript
Episode notes
Funding Curiosity
- Create a vision of your curiosity's potential value.
- Show a path to concrete patient value to garner investment.
FDA's Unique Approach
- The FDA's in-depth analyses are unique and beneficial.
- They focus on data, unlike other agencies that rely on applicants' proofs.
Exilio's Origin
- Exilio Therapeutics explores jumping genes' potential for gene therapy.
- Tal Zaks was intrigued by their idea of improving these elements for gene fixing.
